What it is
Petrelintide is a lab-made, long-acting version of human amylin13. Amylin is a hormone released after you eat that acts as a fullness signal3. Petrelintide works by a different route from drugs based on incretins, such as GLP-1 drugs1. Incretins are hormones released from the gut, such as GLP-19. In early trials, its half-life, the time it takes for half a dose to clear, was about 10 days2. Zealand Pharma and Roche are developing it together6.
What makes it distinct
Its developers designed it to stay stable in a liquid that is close to neutral, neither acidic nor alkaline (near-neutral pH)3. They say this could let it be combined with other drugs in a single product3.
What the evidence shows
Two phase 1 trials tested it in adults of normal weight, overweight or obesity, the longest for 16 weeks2. ZUPREME 1, a phase 2 trial, enrolled 493 adults without type 2 diabetes who had obesity, or overweight plus high blood pressure or unhealthy blood fat levels, and treated them for 42 weeks1. People on petrelintide lost more weight than people on placebo (a dummy injection)1. Nausea was the most common side effect, mostly mild and mostly while the dose was being raised; vomiting was uncommon1. In October 2026, Zealand Pharma announced that ZUPREME-2, a phase 2 trial in 220 adults with type 2 diabetes and overweight or obesity, met its main goal, the change in body weight after 28 weeks compared with placebo58.
Open questions
- Results of phase 3. Three phase 3 trials, ZUPREME-3, -4 and -5, are recruiting, and Zealand Pharma said in October 2026 that the first people had started treatment451011. ZUPREME-3 expects to finish collecting data for its main result in December 20284.
- Whether the effect lasts longer than the 42 weeks of ZUPREME 11.
- Full results in type 2 diabetes. ZUPREME-2 has reported only headline results, in a company announcement5.
Sources
- Garvey WT et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2026;14(11):914-926 (Epub 29 Sep 2026). PMID 42810355
- Braendholt Olsen M et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab 2026;28(7):5915-5925. PMID 42017294
- Fischer Munch H et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem 2025;68(22):23925-23940. PMID 41217931
- ClinicalTrials.gov NCT07843498: ZUPREME-3, Phase III study of once-weekly petrelintide vs placebo in participants with overweight or obesity
- Zealand Pharma company announcement No. 54/2026, 7 October 2026: positive Phase 2 ZUPREME-2 topline results for petrelintide in people with overweight or obesity and type 2 diabetes
- Roche media release, 5 March 2026: Roche announces positive Phase II results for petrelintide
- FDA: Novel Drug Approvals for 2026 (content current as of 10/20/2026)
- ClinicalTrials.gov NCT06926842: Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
- BYETTA (exenatide) injection, FDA prescribing information (DailyMed, AstraZeneca, revised 9/2025)
- ClinicalTrials.gov NCT07843485: ZUPREME-4, Phase III study of once-weekly petrelintide vs placebo in participants with overweight or obesity and type 2 diabetes
- ClinicalTrials.gov NCT07843472: ZUPREME-5, Phase III study of once-weekly petrelintide vs placebo in participants with overweight or obesity and established cardiovascular disease
More in Amylin drugs